Immune response assessment method
AssigneeBaylor Research Institute
InventorsJacques Banchereau, John Connolly, Anna Palucka, Hideki Ueno
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for identifying T-cell epitopes independent of the subject's HLS type by simultaneously analyzing the culture for multiple parameters of immune reactivity to identify at least one epitope wherein the epitopes that elicit immune reactivity of interest in the subset are identified as targeting agents for the subset.
Claims40
A method for identifying one or more immunomodulatory peptides from a subject comprising the steps of:
- culturing the immune cells of the subject in the presence of one or more peptides from an overlapping peptide library taken from an antigenic protein of interest;
- and
- analyzing simultaneously the culture for multiple parameters of immune reactivity such as specificity and cytokine response to epitopes on the peptides, wherein an immunomodulatory peptide is identified by the presence of immune reactivity toward the peptide that is independent of the HLA type of the subject.
A method for identifying one or more immunomodulatory fragments comprising the steps of:
- isolating immune cells from the subject;
- culturing the immune cells in the presence of one or more fragments from the processed peptide library;
- and
- simultaneously analyzing the culture for multiple parameters of immune specificity and cytokine response to the fragments, wherein an immunomodulatory fragment is identified by the presence of immune reactivity toward the fragment.
A method of identifying the type of immune reactivity expressed by a subject towards an antigenic material comprising the steps of:
- isolating and culturing one or more immune cells from a subject in the presence of one or more antigenic fragments;
- identifying the cytokines produced by the immune cells;
- and
- determining the type of immune reactivity based on the coordinated cytokine expression in response to the antigenic material.
A diagnostic method for assessing the immune status of a subject comprising the steps of:
- isolating immune cells from the subject,
- culturing the immune cells in the presence of a series of peptides from an overlapping peptide library taken from an antigenic protein of interest,
- simultaneously analyzing the culture for multiple parameters of immune reactivity to identify at least one immunomodulatory molecule for the subject to determine the type of immune reactivity to the immunomodulatory molecule based on the identification of the cytokines produced, wherein the type of immune reactivity is indicative of the subject's immune status.
A method for predicting a subject's response to therapy comprising the steps of:
- culturing immune cells from the subject in the presence of an overlapping peptide library taken from an antigenic protein of interest;
- analyzing the culture for multiple parameters of immune reactivity to identify at least one immunomodulatory molecule for the subject;
- and
- analyzing the culture for cytokine production to determine the type of immune reactivity to the immunomodulatory molecule based on the identification of the cytokines produced to determine the epitope-specific immune status of the subject prior to treatment as an indicator of treatment outcome.
A method for predicting a subject's disease course and clinical outcome comprising the steps of:
- culturing one or more immune cells from the subject in the presence of a series of peptides from an overlapping peptide library taken from an antigenic protein of interest;
- simultaneously analyzing the culture for cell proliferation and cytokine production profile to determine the type of immune reactivity to the immunomodulatory molecule;
- wherein the cytokine production profile is a marker of disease severity and status of disease progression or regression.
A method of tailoring a therapeutic intervention for a subject comprising the steps of:
- identifying one or more immunomodulatory molecule for the subject based on an analysis of multiple parameters of immune reactivity including an identification of the cytokines produced;
- and
- preparing an epitope-specific immune vaccine comprising the one or more immunomodulatory molecules.
A method for immunomonitoring a subject comprising the steps of:
- determining the epitope-specific immune status of the subject by isolating immune cells from the subject and exposing them to one or more immunomodulatory peptides identified from a peptide library;
- immunizing the subject with one or more of the immunomodulatory peptides identified from the library;
- determining the epitope-specific immune status of the subject by isolating immune cells from the subject after exposure to the one or more immunomodulatory peptides;
- and
- comparing the type of immune response prior to and after immunization to determine changes in the subject's epitope-specific immune status.
A method for treatment of a subject in need of immunotherapy comprising the steps of:
- exposing immune cells from the subject to one or more immunomodulatory peptides to determine the type of immune response triggered by the one or more immunomodulatory peptides;
- treating the subject with immunomodulatory peptides that affect the type of immune response;
- and
- evaluating the type of immune response after treating the subject with one or more immunomodulatory peptides and if necessary modifying the one or more immunomodulatory peptides to change the type of immune response.
A method for identifying and characterizing new therapeutic agents for immunotherapy comprising the steps of:
- culturing isolated immune cells in the presence and absence of an immune modulator and one or more peptides from an overlapping peptide library taken from an antigenic protein of interest;
- simultaneously analyzing the cultures for multiple parameters of immune reactivity such as specificity and cytokine response to epitopes on the peptides;
- and
- comparing the immune reactivity when the immune modulator is present to the immune reactivity when the immune modulator is absent, wherein the inhibition of the immune reactivity is indicative of an immunosuppressive therapeutic agent and wherein the enhancement of the immune reactivity is indicative of an adjuvant.
A therapeutic agent identified by a method comprising the steps of:
- culturing isolated immune cells in the presence and absence of an immune modulator and one or more fragments from an antigenic agents of interest;
- simultaneously analyzing the cultures for multiple parameters of immune reactivity such as specificity and cytokine response to the fragments;
- and
- isolating the immunoreactive cells.
A method for identifying vaccine epitopes comprising the steps of:
- culturing isolated immune cells in the presence of one or more peptides from an overlapping peptide library taken from an antigenic protein of interest;
- analyzing the culture for multiple parameters of immune reactivity and cytokine production to determine the type of immune reactivity to the peptides on the identification of the cytokines produced;
- and
- preparing a vaccine with one or more peptides having the same identified sequence.
A method for characterizing vaccine epitopes comprising the steps of:
- culturing isolated immune cells in the presence of a series of peptides from an overlapping peptide library taken from an antigenic agent;
- analyzing the culture for multiple parameters of immune reactivity and cytokine production in the culture to determine the type of immune reactivity to the one or more peptides,
- wherein the vaccine epitopes are characterized by the immune reactivity they elicit to the antigenic agent.
A composition comprising one or more peptides that are selected to modify the type of immune response isolated from a peptide library identified as immune reactive for a specific individual in which reactive peptides for both Th1 and Th2 T cells have been identified.
A composition comprising one or more peptides that are selected to modify the type of immune response isolated from a peptide library identified as immune reactive for a specific individual in which reactive peptides for both Tc1 and Tc2 T cells have been identified.
Dependencies are inferred from the claim text.